Extra Corporeal Membrane Oxygenation (ECMO) System Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Modality (Veno-Arterial (VA), Veno-Venous (VV), Others), By Application (Respiratory Applications, Cardiac Applications, Extracorporeal Cardiopulmonary Resuscitation (ECPR)), By End-User (Hospitals & Clinics, Ambulatory Care Centers, Others), By Region and Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 575.2 Million
CAGR (2026-2031)	5.86%
Fastest Growing Segment	Hospitals & Clinics
Largest Market	North America
Market Size (2031)	USD 809.49 Million

Market Overview

The Global Extra Corporeal Membrane Oxygenation (ECMO) System Market will grow from USD 575.2 Million in 2025 to USD 809.49 Million by 2031 at a 5.86% CAGR. The Extra Corporeal Membrane Oxygenation (ECMO) system is a specialized medical device utilized to provide prolonged cardiac and respiratory support by oxygenating blood extracorporeally for patients experiencing severe heart or lung failure. Fundamental drivers fueling market growth include the escalating prevalence of chronic cardiopulmonary disorders and a rapidly aging global population susceptible to critical organ insufficiency. Furthermore, the broadening clinical application of these systems in adult intensive care units continues to bolster demand. Illustrating this extensive utilization, according to the Extracorporeal Life Support Organization (ELSO), in its registry report released in April 2025, a cumulative total of 245,291 extracorporeal life support runs were recorded globally through the end of 2024.

However, market expansion confronts a significant challenge regarding the substantial costs associated with device procurement and the intricate nature of the therapy. The requirement for a multidisciplinary team of specialized professionals to manage the equipment and mitigate serious risks, such as bleeding or infection, restricts accessibility in smaller healthcare institutions. Consequently, the high financial burden and the critical shortage of trained expertise remain primary obstacles impeding the broader adoption of this technology across diverse healthcare infrastructures.

Key Market Drivers

Technological advancements in device portability and miniaturization are significantly propelling the Global Extra Corporeal Membrane Oxygenation (ECMO) System Market by enabling rapid deployment outside traditional hospital settings. Innovations in compact, lightweight systems allow for earlier intervention and safer patient transport, expanding the scope of life support to ambulances and smaller clinics. Validating this trend, according to Inspira Technologies, May 2024, in the 'INSPIRA ART100 Receives FDA 510(k) Clearance' press release, the company received regulatory clearance for its INSPIRA ART100 system, a new generation of blood oxygenation technology designed to minimize patient invasiveness. Furthermore, substantial investment in research is accelerating these capabilities; according to Johns Hopkins Medicine, December 2024, in the 'Johns Hopkins Medicine Awarded More Than $18 Million for Creation of New ECMO and Life-Support System' article, the institution received over $18 million in funding to develop a portable, rapid-deployment ECMO device for field use.

Concurrently, the rising global prevalence of severe cardiopulmonary disorders acts as a critical determinant driving the sustained demand for mechanical circulatory support. As the incidence of chronic heart failure and respiratory distress escalates, the necessity for bridging therapies to stabilize patients for recovery or transplantation becomes more acute. Underscoring this burden, according to the American Heart Association, January 2024, in the '2024 Heart Disease and Stroke Statistics: A Report of US and Global Data', cardiovascular disease continues to account for more than 800,000 deaths annually in the United States alone, highlighting the immense clinical need for advanced interventions like ECMO. This growing patient pool compels healthcare providers to integrate extracorporeal support systems into standard critical care protocols to manage high-mortality conditions effectively.

Download Free Sample Report

Key Market Challenges

The high financial burden and the critical shortage of trained expertise significantly impede the expansion of the Global ECMO System Market. The complexity of extracorporeal life support requires not only expensive capital equipment but also a dedicated, multidisciplinary team of specialists available around the clock. This necessity creates a substantial barrier to entry for smaller healthcare institutions and developing regions, confining the market primarily to large, well-funded academic centers.

Consequently, the inability to deploy these systems universally limits the potential install base and procedure volumes. The therapy's intricate nature demands rigorous management to mitigate risks, further intensifying the need for scarce, highly skilled professionals. Illustrating this clinical complexity, according to the Extracorporeal Life Support Organization, in its international registry report released in April 2025, the overall survival rate to discharge or transfer for these high-acuity patients was 64%. Such outcomes highlight the steep proficiency curve required, ensuring that the shortage of qualified personnel remains a direct restraint on broader market adoption.

Key Market Trends

The rapid adoption of Extracorporeal Cardiopulmonary Resuscitation (ECPR) is reshaping emergency protocols by providing immediate circulatory support for refractory cardiac arrest. This technique extends the critical window for intervention in cases where conventional resuscitation fails, driving increased implementation across advanced medical centers. As institutions standardize their cannulation strategies, clinical success rates for this high-acuity procedure are demonstrating a marked upward trajectory. Validating this improvement, according to the Annals of Emergency Medicine, January 2025, in the 'Extracorporeal Cardiopulmonary Resuscitation: Outcomes Improve With Center Experience' article, the proportion of ECPR patients achieving favorable neurologic outcomes increased to 37% by the end of the studied period.

Simultaneously, a distinct shift towards awake and ambulatory ECMO protocols is optimizing care for patients awaiting organ transplantation. This approach reduces reliance on sedation and mechanical ventilation, enabling patients to maintain physical mobility and preventing muscle atrophy prior to surgery. By focusing on rehabilitation during extracorporeal support, healthcare providers are significantly enhancing candidate stability and post-transplant viability. Underscoring the efficacy of this strategy, according to the ASAIO Journal, July 2024, in the 'Ambulatory Extracorporeal Membrane Oxygenation Use in Patients Listed for Lung Transplant' article, the 90-day waitlist survival rate for ambulatory veno-venous ECMO patients reached 86%, substantially outperforming non-ambulatory cohorts.

Segmental Insights

The Hospitals and Clinics segment constitutes the fastest-growing area of the Global Extra Corporeal Membrane Oxygenation System Market, primarily due to rising admission rates for acute respiratory and cardiac failure. This growth is supported by an increasing prevalence of lifestyle-related cardiovascular diseases and respiratory conditions that require prolonged life support. Additionally, streamlined device approvals by regulatory authorities such as the U.S. Food and Drug Administration have facilitated broader equipment adoption across medical facilities. As institutions expand their intensive care infrastructure to manage high-acuity patients effectively, the demand for onsite extracorporeal support systems continues to accelerate.

Regional Insights

North America maintains a leading position in the global Extra Corporeal Membrane Oxygenation market, driven by the high prevalence of chronic respiratory and cardiovascular conditions requiring advanced life support. The region benefits from established healthcare infrastructure and comprehensive reimbursement frameworks that increase procedure accessibility. Market stability is further reinforced by the strategic influence of the Extracorporeal Life Support Organization, which drives clinical adoption through standardized training and data registries. Additionally, the U.S. Food and Drug Administration plays a crucial role in maintaining safety standards and facilitating prompt product approvals, securing the region's strong market standing.

Recent Developments

• In April 2025, Eurosets unveiled the Xtreme Rescue, a highly portable extracorporeal life support (ECLS) device designed specifically for emergency interventions and patient transport. Presented at the EuroELSO congress in Milan, the system was characterized by its lightweight design, utilizing materials such as carbon fiber and titanium to facilitate use in ambulances and helicopters. The company positioned this launch as a breakthrough in making ECMO capabilities more accessible in out-of-hospital settings and remote locations. Additionally, the device was designed to operate in synergy with the company's existing Colibrì system, expanding the range of adaptable solutions available to clinicians for cardiac and pulmonary support.
• In March 2025, Terumo Corporation introduced the Capiox Centrifugal Pump Controller SP-300, a new model within its portfolio of extracorporeal circulation technologies. This device was engineered to serve as a core component of ECMO systems used for emergency cardiopulmonary resuscitation and the treatment of severe respiratory failure. The launch addressed the growing medical demand for safer, long-term management of patients on life support by incorporating enhanced sensor capabilities to detect abnormalities such as thrombus formation in blood circuits. This development highlighted the company's continuous focus on improving the durability and safety profiles of its life-support equipment for critical care environments.
• In October 2024, Fresenius Medical Care, through its subsidiary Xenios AG, launched the Xenios 2.0, a next-generation system dedicated to extracorporeal life support (ECLS) and ECMO therapies. The new console was developed to cover a full range of patient needs, from neonates to adults, and received approval under the European Medical Device Regulation (MDR). Key advancements in the system included an intuitive graphical user interface, integrated pressure sensors to enhance safety, and improved connectivity features for seamless data integration. This product launch reinforced the company's commitment to providing versatile and safer solutions for critically ill patients requiring heart and lung support.
• In May 2024, Inspira Technologies announced that it received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its INSPIRA ART100 system. This regulatory milestone allowed the company to introduce its advanced extracorporeal blood oxygenation technology to the U.S. market, initially indicated for cardiopulmonary bypass procedures. The system was designed to enhance patient outcomes by minimizing blood damage during extracorporeal circulation, a critical factor in both short-term surgical support and longer-term treatments such as Extra Corporeal Membrane Oxygenation (ECMO). This approval marked a significant step in the company's strategy to deploy its proprietary technologies across the global respiratory and life support market.

Key Market Players

• Alung Technologies Inc.
• Eurosets
• Getinge AB
• Medtronic PLC
• Microport Scientific Corporation
• Nipro Medical Corporation
• Terumo Medical Corporation
• Abbott Laboratories
• Fresenius Medical Care Company

By Modality	By Application	By End-User	By Region
Veno-Arterial (VA) Veno-Venous (VV) Others	Respiratory Applications Cardiac Applications Extracorporeal Cardiopulmonary Resuscitation (ECPR)	Hospitals & Clinics Ambulatory Care Centers Others	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Extra Corporeal Membrane Oxygenation (ECMO) System Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Extra Corporeal Membrane Oxygenation (ECMO) System Market, By Modality:

• Veno-Arterial (VA)
• Veno-Venous (VV)
• Others

• Extra Corporeal Membrane Oxygenation (ECMO) System Market, By Application:

• Respiratory Applications
• Cardiac Applications
• Extracorporeal Cardiopulmonary Resuscitation (ECPR)

• Extra Corporeal Membrane Oxygenation (ECMO) System Market, By End-User:

• Hospitals & Clinics
• Ambulatory Care Centers
• Others

• Extra Corporeal Membrane Oxygenation (ECMO) System Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE